Showing results (51-60 of 173) with videos related to
Sort By:
Pageof 18
Arthritis and Rheumatism|October 15, 2003
Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse eventsYusuf Yazici, Doruk Erkan, Stephen A PagetBest Practice & Research. Clinical Haematology|December 9, 2022
COVID-19 and antiphospholipid antibodiesAyesha Butt, Doruk Erkan, Alfred Ian LeeCurrent Opinion in Rheumatology|November 25, 2015
Recognition and management of antiphospholipid syndromeMaria Gerosa, Pier Luigi Meroni, Doruk ErkanCurrent Opinion in Immunology|April 21, 2026
Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanismsEcem Sevim, Zeynep B Erton, Doruk ErkanNature Reviews. Drug Discovery|December 2, 2004
Challenges in bringing the bench to bedside in drug development for SLEJoan T Merrill, Doruk Erkan, Jill P BuyonJournal of Intensive Care Medicine|May 5, 2006
Catastrophic antiphospholipid syndromeSetu K Vora, Ronald A Asherson, Doruk ErkanEuropean Journal of Rheumatology|March 7, 2023
Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?Yiannis Ioannou, Timothy Beukelman, Miranda Murray, et al.Frontiers in Immunology|October 2, 2024
Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseasesDoruk Erkan, Joann Vega, Tyler O'Malley, et al.Clinical Reviews in Allergy & Immunology|December 4, 2008
Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapseSilvia Bucciarelli, Doruk Erkan, Gerard Espinosa, et al.Pageof 18